Claims for Patent: 11,413,323

Summary for Patent: 11,413,323

Title:	Ophthalmic composition for treatment of dry eye disease
Abstract:	The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.
Inventor(s):	Chiara Silvana Leo, Sonja KRÖSSER, Thomas Schlüter, Alice MEIDES
Assignee:	Novaliq GmbH
Application Number:	US17/228,309
Patent Claims:	1. A method for improving symptoms of visual impairment or visual disturbance in a patient suffering from dry eye disease, wherein the patient is characterized by having at least one eye with a total ocular surface disease index score (OSDI) of equal or greater than 45 at baseline, wherein the method provides a reduction in the total corneal fluorescein staining score (NEI scale) by three or more units, and wherein the method comprises the step of administering to the eye of the patient a composition comprising 0.1% (w/v) cyclosporine dissolved in 1-(perfluorobutyl)-pentane and up to about 1% (w/w) ethanol; wherein said composition is administered twice per day per eye, at a dose of a single drop per eye of a volume of about 8 to 11 μL. 2. The method of claim 1, wherein the method comprises administering the composition for a period of at least four weeks. 3. The method of claim 1, wherein the method provides an improvement of any one or a combination of blurred vision, sensitivity to light, pain or sore eyes, poor vision, or problems in reading, driving at night, working on a computer or bank machine, and watching television. 4. The method of claim 1, wherein the composition is administered twice per day per eye, at a dose of a single drop per eye of a volume of about 8 to 10 μL. 5. The method of claim 1, wherein the patient has at least one eye with a total ocular surface disease index score (OSDI) of equal or greater than 55, and at least one eye with: (i) a total corneal fluorescein staining score of 11 or higher (NEI scale); or (ii) a central corneal fluorescein staining in the range of 1 to 3 (NEI scale); or (iii) a total lissamine green conjunctival staining score in the range of 2 to 6; or (iv) an unanesthetized Schirmer's test score in the range of 2 to 8 mm; or (v) any combination of (i) to (iv); or (vi) any combination of (i) to (iv), with the specified values in both eyes. 6. The method according to claim 5, wherein the central corneal fluorescein staining value is in the range of 2 to 3 (NEI scale). 7. The method according to claim 5, wherein the lissamine green conjunctival staining score is in the range of 3 to 5. 8. The method according to claim 1, wherein method provides a reduction in the total corneal fluorescein staining score (NEI scale) of at least 3 units within a treatment period of at least 8 weeks. 9. A method of treating and/or ameliorating the symptoms of dryness associated with dry eye disease in a patient in need thereof, wherein the method comprises topically administering an ophthalmic composition comprising 0.1% (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane, and up to about 1.0% (w/w) ethanol, wherein the composition is administered in a dose of a single drop per eye in a volume of about 8 to 10 μL, twice per day per eye; wherein the composition is effective in reducing the frequency of the symptom of dryness and/or the severity of dryness within 4 weeks after start of treatment; and wherein the patient has at least one eye with a total ocular surface disease index score (OSDI) of equal or greater than 55; and wherein the patient has at least one eye with: (i) a total corneal fluorescein staining score in the range of 10 to 15 (NEI scale); or (ii) a central corneal fluorescein staining value in the range of 2 to 3 (NEI scale); or (iii) a lissamine green conjunctival staining score in the range of 2 to 6; or (iv) an unanesthetized Schirmer's test score in the range of 2 to 8 mm; or (v) any combination of (i) to (iv); or (vi) any combination of (i) to (iv), with the specified values in both eyes. 10. The method of claim 9, wherein the effectiveness in reduction in the frequency of dryness or the severity of dryness, or combination thereof is determined by visual analog scale (VAS) testing on a scale of 0 to 100%, wherein frequency of dryness and awareness of dry eye symptoms are measured on a scale of 0 to 100% as the percentage of time said symptom(s) is experienced by a patient and wherein the severity of dryness is measured on a scale of 0 to 100% as the percentage level of discomfort experienced by the patient. 11. The method of claim 9, wherein the composition is effective in reducing the frequency of dryness and/or the severity of dryness by at least 25%, after four weeks, as determined by visual analog scale (VAS) testing on a scale of 0 to 100%, wherein frequency of dryness and awareness of dry eye symptoms are measured on a scale of 0 to 100% as the percentage of time said symptom(s) is experienced by a patient and wherein the severity of dryness is measured on a scale of 0 to 100% as the percentage level of discomfort experienced by the patient. 12. The method of claim 9, wherein the method is effective in reducing in a patient the total corneal fluorescein staining score in at least one eye (sum of inferior, superior, central, nasal, and temporal staining scores; NEI scale), by at least 3 grades after 4 weeks of treatment. 13. The method of claim 9, wherein the dry eye disease is aqueous-deficient dry eye disease. 14. The method of claim 9, wherein the dry eye disease is evaporative dry eye disease. 15. The method of claim 9, wherein the patient is non-responsive, or insufficiently responsive, to treatment with aqueous ophthalmic eye drop compositions. 16. A method of treating dry eye disease, the method comprising the step of topically administering an ophthalmic composition comprising 0.1% (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane and up to about 1.0% (w/w) ethanol to an eye of a patient; wherein the composition is administered twice per day per eye, and as a single drop having a volume of about 8 to 10 μL; wherein the patient has at least one eye with a total ocular surface disease index (OSDI) score of equal or greater than 55; and wherein the patient has at least one eye with any one or combination of criteria selected from the group consisting of: (i) a total corneal fluorescein staining score of 11 or higher (NEI scale); (ii) a central corneal fluorescein staining value in the range of 2 to 3 (NEI scale); (iii) a total lissamine green conjunctival staining score in the range of 2 to 6; (iv) an unanesthetized Schirmer's test score in the range of 2 to 8 mm; and (v) any one or combination of (i) to (iv); or (vi) any combination of (i) to (iv), with the specified values in both eyes. 17. The method of claim 16, wherein treatment is effective in reducing ocular surface damage selected from ocular surface damage of the central corneal region and ocular surface damage of the inferior corneal region. 18. The method of claim 16, wherein the dry eye disease is aqueous-deficient dry eye disease. 19. The method of claim 16, wherein the dry eye disease is evaporative dry eye disease. 20. The method of claim 16, wherein the patient is non-responsive, or insufficiently responsive to treatment with aqueous ophthalmic eye drop compositions. 21. The method of claim 16, wherein the patient has a history of dry eye disease in one or both eyes for at least six months. 22. The method of claim 16, wherein the patient has at least one eye, or both eyes with an inferior corneal fluorescein staining (NEI scale) score of 2 or higher.